PDIA3 is overexpressed in most cervical cancers [22], malignant stages of prostate cancer [23], uveal melanoma [24], gliomas [25], clear cell renal cell carcinoma [26], and hepatocellular carcinoma (HCC) [27]. Here, PDIA3 is linked to central nervous system cancer.